VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Are at least 18 years of age                       │ Are at least 18 years of age                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Demonstrate a positive cough stress test during    │ Demonstrate a positive cough stress test during    │     100 │
│ complex multi-channel urodynamic testing           │ complex multi-channel urodynamic testing           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Demonstrate impact of stress urinary incontinence  │ Demonstrate impact of stress urinary incontinence  │     100 │
│ on quality of life questionnaire                   │ on quality of life questionnaire                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are able to comprehend and sign a written informed │ Are able to comprehend and sign a written informed │     100 │
│ consent                                            │ consent                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Understand and are willing to comply with the      │ Understand and are willing to comply with the      │     100 │
│ study requirements, including agreeing to be       │ study requirements, including agreeing to be       │         │
│ available for the follow-up evaluations            │ available for the follow-up evaluations            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are psychologically stable and suitable for        │ Are psychologically stable and suitable for        │     100 │
│ interventions determined by the investigator       │ interventions determined by the investigator       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are ambulatory and able to use a toilet            │ Are ambulatory and able to use a toilet            │     100 │
│ independently                                      │ independently                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients                                           │ Patients                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Who are pregnant or planning to become pregnant    │ Who are pregnant or planning to become pregnant    │     100 │
│ during the study or in the future                  │ during the study or in the future                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With a bleeding condition or on anti-coagulant     │ With a bleeding condition or on anti-coagulant     │     100 │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With immunosuppression (i.e. HIV, lymphoma)        │ With immunosuppression (i.e. HIV, lymphoma)        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With multiple sclerosis or other progressive       │ With multiple sclerosis or other progressive       │     100 │
│ neurological disease                               │ neurological disease                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With evidence of a local or systemic infection,    │ With evidence of a local or systemic infection,    │     100 │
│ including urinary tract infection                  │ including urinary tract infection                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With evidence of intrinsic sphincter deficiency as │ With evidence of intrinsic sphincter deficiency as │     100 │
│ defined by a maximal urethral closure pressure of  │ defined by a maximal urethral closure pressure of  │         │
│ \<20 cm H2O                                        │ <20 cm H2O                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous sub-urethral sling                        │ Previous sub-urethral sling                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Predominant overactive bladder symptoms            │ Predominant overactive bladder symptoms            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With a elevated post-void residual (defined as PVR │ With a elevated post-void residual (defined as PVR │      99 │
│ \> 100cc)                                          │ > 100cc)                                           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                │   Score │
╞═══════════════════════════════════╪══════════════════════════════╪═════════╡
│ Must be FEMALE                    │ Previous sub-urethral sling  │      29 │
├───────────────────────────────────┼──────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Are at least 18 years of age │      39 │
╘═══════════════════════════════════╧══════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 93.0
OverAll Ratio: 95.5
